BrainsWay (BWAY) Fundamentals 2026 — P/E 72.4x, Revenue Analysis | SniperIQ

6.29 on the NASDAQ. This SniperIQ fundamentals page covers BrainsWay's valuation (P/E 72.4x, P/B 8.2x), profitability (net margin 14.6%), revenue ($52M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is BrainsWay's market cap?

BrainsWay (BWAY) has a market capitalization of approximately $639M, trading at

6.29 on the NASDAQ. Market cap moves with the live share price.

What is BrainsWay's P/E ratio?

BrainsWay's trailing twelve-month P/E ratio is 72.4x, with a price-to-book (P/B) of 8.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is BrainsWay?

BrainsWay runs a net profit margin of 14.6%, a gross margin of 75.5%, and an operating margin of 10.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does BrainsWay generate?

BrainsWay reported revenue of $52M for fiscal year 2025, with net income of $8M and earnings per share (EPS) of 0.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does BrainsWay pay a dividend?

BrainsWay does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is BrainsWay financially healthy?

BrainsWay carries a debt-to-equity ratio of 0.09x and a current ratio of 3.34x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is BrainsWay a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BrainsWay (BWAY) the key facts are: market cap $639M, P/E 72.4x, revenue $52M, 52-week range 5.6765-17.352. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.